May 17, 2020

Pelican Products buys Minnesota Thermal Science

Torrance-based Pelican Products
high performance protective
Admin
2 min
Pelican Products buys Minnesota Thermal Science
Torrance-based Pelican Products has acquired Minnesota Thermal Science. Minnesota Thermal Science will merge with Pelicans already established BioPharm...

Torrance-based Pelican Products has acquired Minnesota Thermal Science. Minnesota Thermal Science will merge with Pelican’s already established BioPharma division. Pelican Products is a leader in design and manufacture of high performance protective case solutions and advanced portable lighting systems.

The deal is worth $26 million.

“ This transaction will provide us enhanced sales and distribution capabilities globally, as well as additional engineering expertise and other resources to increase our offerings to the pharmaceutical and life science industries are controlled packaging solutions for the safe transport of pharmaceuticals, tissue, biologics, diagnostics, blood and other healthcare product also said," MTS said. The company also said, "We are already planning an accelerated product development program which will significantly enhance our solution set and associated cold chain services,” said MTS.

 MTS said its entire management team will remain intact and become an integral part of Pelican’s BioPharma division. The division will be headed up by Tom Anderson, senior vice president — Pelican BioPharma.

Dick Peters, Vice President of Global Operations and Services — BioPharma, and Kevin Lawler, Vice President of sales — BioPharma will be reporting to Mr. Anderson. 

Jeff Wodrich will continue in his key role as director of business development for the new organization and we will be integrating the rest of the Pelican BioPharma team.

MTS was founded in 2004 and has 35 employees at its Plymouth facility. Pelican Products has 1,250 employees. MTS has been growing revenue 50 percent per year during the past five years. Minnesota Thermal Science was part of A. Johnson Enterprises of Baxter.

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article